[1]胡晓娜,尹雅琪,谷伟军,等.TRAb水平与甲状腺相关性眼病活动度及严重程度的相关性分析[J].国际内分泌代谢杂志,2022,42(05):334-338.[doi:10.3760/cma.j.cn121383-20220306-03013]
　Hu Xiaona,Yin Yaqi,Gu Weijun,et al.Correlation between TRAb and thyroid-associated ophthalmopathy activity/severity scores[J].International Journal of Endocrinology and Metabolism,2022,42(05):334-338.[doi:10.3760/cma.j.cn121383-20220306-03013]
点击复制

TRAb水平与甲状腺相关性眼病活动度及严重程度的相关性分析()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
42
期数:
2022年05期
页码:
334-338
栏目:
论著
出版日期:
2022-09-20

文章信息/Info

Title:
Correlation between TRAb and thyroid-associated ophthalmopathy activity/severity scores
作者:
胡晓娜1; 2; 尹雅琪1; 谷伟军1; 吕朝晖1; 母义明1
1解放军总医院第一医学中心内分泌科,北京 100853; 2解放军医学院,北京 100853
Author(s):
Hu Xiaona1; 2;  Yin Yaqi1;  Gu Weijun1;  Lyu Zhaohui2;  Mu Yiming2.
1Department of Endocrinology, the First Medical Centre, Chinese PLA General Hospital, Beijing 100853, China; 2Medical School of Chinese PLA, Beijing 100853, China
关键词:
甲状腺相关性眼病;  促甲状腺激素受体抗体;  活动度;  严重程度
Keywords:
Thyroid-associated ophthalmopathy;  TSH receptor autoantibodies;  Activity;  Severity
DOI:
10.3760/cma.j.cn121383-20220306-03013
摘要:
目的 探讨促甲状腺激素受体抗体水平(TRAb)与甲状腺相关性眼病活动度及严重程度的相关性。方法 回顾性分析1993年8月至2020年12月于解放军总医院诊断为甲状腺相关性眼病且未接受眼病相关治疗患者的临床资料,分析血清TRAb水平与甲状腺相关性眼病活动度及严重程度的相关性。结果(1)年满18周岁且眼病病程≤18个月并有血清TRAb检测结果者共180例,眼病起病年龄为(46.06±12.47)岁,其中男性84例,女性96例,眼病持续时间5.0(3.0,9.0)个月,CAS评分≥3分93例,NOSPECS分级≥4级165例,按欧洲Graves眼病专家组指南严重程度分级轻度、中重度和危及视力分别有72例、98例和10例。(2)中重度及危及视力患者血清TRAb水平明显高于轻度患者[12.8(4.0, 30.1)U/L比6.2(3.2, 14.8)U/L,P=0.004],活动性患者血清TRAb水平高于非活动性患者[12.6(3.4,31.0)U/L比6.5(3.4, 17.6)U/L,P=0.006],美国甲状腺协会严重程度分级≥4级与<4级患者血清TRAb水平无明显差异。(3)不同活动度及严重程度患者的血清TRAb阳性率之间差异无统计学意义。(4)单因素回归分析结果显示,血清TRAb水平与中重度及危及视力患病风险的升高相关(OR=2.02,P=0.001),且和活动性相关(OR=1.5,P=0.016),多因素回归分析显示这种相关性仍存在。结论 血清TRAb水平与甲状腺相关性眼病活动度和严重程度相关,随着抗体水平的增加,患者进展为活动性和中重度及危及视力的风险可能增加。
Abstract:
Objective To investigate the association between the levels of serum TSH receptor autoantibodies(TRAb)and thyroid-associated ophthalmopathy(TAO)activity/severity scores.Methods A retrospective analysis was conducted on the data of TAO in Chinese PLA General Hospital from August 1993 to December 2020, and the Correlation between the levels of TRAb and TAO activity/severity scores was analyzed.Results(1)A total of 180 patients aged 18 years or older with eye disease course ≤18 months and serum TRAb results were included. The onset age of TAO was 46.06±12.47 years, including 84 males and 96 females. The duration of TAO was 5.0(3.0,9.0)months. CAS scores ≥3 points were 93 cases. NOSPECS grades by American Thyroid Association ≥4 were 165 cases. According to European Group on Graves' Orbitopathy(EUGOGO)guidelines, 72 cases were mild, 98 cases were moderate-to-severe, and 10 cases were sight-threatening.(2)The serum TRAb levels of patients with moderate-to-severe/sight-threatening and active TAO based on EUGOGO guidelines was significantly higher than that of mild and inactive patients [12.8(4.0, 30.1)U/L vs. 6.2(3.2, 14.8)U/L, P=0.004], [12.6(3.4,31.0)U/L vs. 6.5(3.4, 17.6)U/L,P=0.006]. There was no significant difference in serum TRAb levels between patients with NOSPESC grades ≥4 and <4.(3)There was no statistical difference between positive rates of serum TRAb and TAO activity/severity scores.(4)Univariate regression analysis showed that serum TRAb levels were associated with increased risk of moderate-to-severe and sight-threatening(OR=2.02, P=0.001)and activity(OR=1.5, P=0.016). Multivariate regression analysis showed that this association still existed.Conclusions Serum TRAb levels are associated with the activity and severity of TAO. With antibody levels increasing, patients may be at increased risk of progression to active and moderate-to-severe/sight-threatening grade.

参考文献/References:

[1] Kahaly GJ,Diana T.TSH receptor antibody functionality and nomenclature[J].Front Endocrinol(Lausanne),2017,8:28.DOI:10.3389/fendo.2017.00028.
[2] Mukasa K,Yoshimura Noh J,Kouzaki A,et al.TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients[J].Endocr J,2016,63(2):151-157.DOI:10.1507/endocrj.EJ15-0137.
[3] George A,Diana T,Längericht J,et al.Stimulatory thyrotropin receptor antibodies are a biomarker for Graves' orbitopathy[J].Front Endocrinol(Lausanne),2021,11:629925.DOI:10.3389/fendo.2020.629925.
[4] Lytton SD,Ponto KA,Kanitz M,et al.A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy[J].J Clin Endocrinol Metab,2010,95(5):2123-2131.DOI:10.1210/jc.2009-2470.
[5] Jang SY,Shin DY,Lee EJ,et al.Correlation between TSH receptor antibody assays and clinical manifestations of Graves' orbitopathy[J].Yonsei Med J,2013,54(4):1033-1039.DOI:10.3349/ymj.2013.54.4.1033.
[6] Ponto KA,Kanitz M,Olivo PD,et al.Clinical relevance of thyroid-stimulating immunoglobulins in graves' ophthalmopathy[J].Ophthalmology,2011,118(11):2279-2285.DOI:10.1016/j.ophtha.2011.03.030.
[7] Nicolì F,Lanzolla G,Mantuano M,et al.Correlation between serum anti-TSH receptor autoantibodies(TRAbs)and the clinical feature of Graves' orbitopathy[J].J Endocrinol Invest,2021,44(3):581-585.DOI:10.1007/s40618-020-01353-y.
[8] Woo YJ,Jang SY,Lim TH,et al.Clinical association of thyroid stimulating hormone receptor antibody levels with disease severity in the chronic inactive stage of Graves' orbitopathy[J].Korean J Ophthalmol,2015,29(4):213-219.DOI:10.3341/kjo.2015.29.4.213.
[9] Noh JY,Hamada N,Inoue Y,et al.Thyroid-stimulating antibody is related to Graves' ophthalmopathy,but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease[J].Thyroid,2000,10(9):809-813.DOI:10.1089/thy.2000.10.809.
[10] Gerding MN,van der Meer JW,Broenink M,et al.Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy[J].Clin Endocrinol(Oxf),2000,52(3):267-271.DOI:10.1046/j.1365-2265.2000.00959.x.
[11] Bartalena L,Kahaly GJ,Baldeschi L,et al.The 2021 European Group on Graves' orbitopathy(EUGOGO)clinical practice guidelines for the medical management of Graves' orbitopathy[J].Eur J Endocrinol,2021,185(4):G43-G67.DOI:10.1530/EJE-21-0479.
[12] Werner SC.Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association[J].J Clin Endocrinol Metab,1977,44(1):203-204.DOI:10.1210/jcem-44-1-203.
[13] Rotondi M,Virili C,Pinto S,et al.The clinical phenotype of Graves' disease occurring as an isolated condition or in association with other autoimmune diseases[J].J Endocrinol Invest,2020,43(2):157-162.DOI:10.1007/s40618-019-01094-7.
[14] Hales IB,Rundle FF.Ocular changes in Graves' disease.A long-term follow-up study[J].Q J Med,1960,29:113-126.DOI:10.1093/oxfordjournals.qjmed.a066862.
[15] Wakelkamp IM,Bakker O,Baldeschi L,et al.TSH-R expression and cytokine profile in orbital tissue of active vs.inactive Graves' ophthalmopathy patients[J].Clin Endocrinol(Oxf),2003,58(3):280-287.DOI:10.1046/j.1365-2265.2003.01708.x.
[16] Hai YP,Lee ACH,Frommer L,et al.Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy[J].J Endocrinol Invest,2020,43(2):123-137.DOI:10.1007/s40618-019-01116-4.

相似文献/References:

[1]娜仁其木格 李冬梅 忻荣荣 贾海英 郑雁红.低滴度TRAb原发性甲状腺毒症患者TRAb 水平与甲状腺131I摄取率的相关性研究[J].国际内分泌代谢杂志,2020,40(03):159.[doi:10.3760/cma.j.issn.1673-4157.2020.03.004]
　Na Renqimuge,Li Dongmei,Xin Rongrong,et al.Association between TRAb level and thyroid iodine uptake rate in primary thyrotoxic patients with low titer TRAb[J].International Journal of Endocrinology and Metabolism,2020,40(05):159.[doi:10.3760/cma.j.issn.1673-4157.2020.03.004]
[2]冯周琴,邵加庆,叶小珍.眼眶成纤维细胞异常脂肪分化与甲状腺相关性眼病关系的研究进展[J].国际内分泌代谢杂志,2021,41(01):15.[doi:10.3760/cma.j.cn121383-20200508-05011]
　Feng Zhouqin,Shao Jiaqing,Ye Xiaozhen..Abnormal adipogenesis originated from orbital fibroblasts in thyroid-associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2021,41(05):15.[doi:10.3760/cma.j.cn121383-20200508-05011]
[3]陆晨雅,陈国芳,徐书杭,等.甲状腺相关性眼病处理的新视角:局部注射疗法[J].国际内分泌代谢杂志,2023,43(02):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]
　Lu Chenya,Chen Guofang,Xu Shuhang,et al.Therapy insight: local injections for the treatment of thyroid associated ophthalmopathy[J].International Journal of Endocrinology and Metabolism,2023,43(05):104.[doi:10.3760/cma.j.cn121383-20210426-04068 ]

备注/Memo

备注/Memo:
通信作者:吕朝晖,metabolism301@126.com
更新日期/Last Update: 2022-09-10